Based on research performed at Columbia University by a founder of the firm, BioPhyZica was organized around development of a new class of therapeutics called "Capillary Sealing Therapeutics" - drugs utilized in treatment of many diseases caused by tissue injury and are char acterized by increased capillary permeability/leak leading to detrimental swelling/edema. The firm appears to have gone out of business. These drugs are unique in that they act through both biophysical as well as biochemical mechanisms. Most previous drugs unsuccessfully attempted to attack the problem of this harmful edema from only a biochemical mechanism. Extremely damaging edema exists in many disease states, many of which represent significant markets with unmet medical needs (i.e. stroke, sepsis, ARDS, cardio-pulmonary bypass surgery, head injuries, etc). This new technology is based on research performed at Columbia University by BioPhyZica co-founder Dr. Bashir Zikria, as well as patents resulting from BioPhyZica's independent research. This intellectual property portfolio, as well as production barriers, will give the company broad proprietary coverage in this new class of therapeutics.
